STRATA Skin Sciences, Inc.(SSKN)Earnings, Financials & Key Ratios
SSKN•NASDAQ
$0.14
$5M mkt cap·Price updated May 6, 2026
AboutSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.Show more
- Revenue$34M+0.6%
- EBITDA-$4M-46.1%
- Net Income-$10M+6.9%
- EPS (Diluted)-0.26+16.1%
- Gross Margin56.85%+2.7%
- EBITDA Margin-11.76%-45.2%
- Operating Margin-27.58%-6.9%
- Net Margin-30.05%+7.4%
- ROE-114.22%-82.0%
- ROIC-38.9%-39.8%
- Debt/Equity3.31+168.3%
- Interest Coverage-4.39+16.3%
SSKN Key Insights
STRATA Skin Sciences, Inc. (SSKN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗High debt to equity ratio of 3.3x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SSKN Price & Volume
STRATA Skin Sciences, Inc. (SSKN) stock price & volume — 10-year historical chart
Loading chart...
SSKN Growth Metrics
STRATA Skin Sciences, Inc. (SSKN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years43.36%
5 Years1.22%
3 Years3.84%
TTM-5.19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-335.46%
Return on Capital
10 Years-18.97%
5 Years-20.45%
3 Years-24.63%
Last Year-36.03%
SSKN Peer Comparison
STRATA Skin Sciences, Inc. (SSKN) competitors in Aesthetics, dermatology, and wound care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 106.45M | 5.21 | -7.24 | -29.11% | -15.49% | -45.4% | 1.28 | |
 SKIN | 120.86M | 0.93 | -5.83 | -10.02% | -3.16% | -15.42% | 6.20 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 INMD | 861.05M | 13.59 | 9.50 | -6.16% | 25.33% | 14.52% | 0.02 | |
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 ESTA | 2.19B | 74.68 | -43.42 | 27.14% | -24.19% | -201.79% | 11.23 | |
 GMED | 12.07B | 89.22 | 22.76 | 16.65% | 18.3% | 12.4% | 0.03 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare SSKN vs Peers
STRATA Skin Sciences, Inc. (SSKN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SSKN Income Statement
STRATA Skin Sciences, Inc. (SSKN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 31.76M | 31.45M | 29.86M | 31.59M | 23.09M | 29.98M | 36.16M | 33.36M | 33.56M | 30.98M |
| Revenue Growth % | 71.71% | -0.97% | -5.07% | 5.8% | -26.9% | 29.83% | 20.63% | -7.75% | 0.61% | -5.19% |
| Cost of Goods Sold | 12.64M | 13.5M | 12.73M | 11.32M | 8.96M | 10.13M | 14.39M | 14.9M | 14.48M | 13.09M |
| COGS % of Revenue | 39.79% | 42.92% | 42.66% | 35.83% | 38.79% | 33.78% | 39.8% | 44.66% | 43.15% | - |
| Gross Profit | 19.12M▲ 0% | 17.95M▼ 6.1% | 17.12M▼ 4.6% | 20.27M▲ 18.4% | 14.13M▼ 30.3% | 19.85M▲ 40.4% | 21.77M▲ 9.7% | 18.46M▼ 15.2% | 19.08M▲ 3.4% | 17.89M▲ 0% |
| Gross Margin % | 60.21% | 57.08% | 57.34% | 64.17% | 61.21% | 66.22% | 60.2% | 55.34% | 56.85% | 57.76% |
| Gross Profit Growth % | 300.36% | -6.12% | -4.63% | 18.4% | -30.27% | 40.44% | 9.66% | -15.19% | 3.36% | - |
| Operating Expenses | 22.72M | 20.36M | 20.48M | 23.28M | 18.21M | 24.25M | 26.42M | 27.07M | 28.34M | 28.22M |
| OpEx % of Revenue | 71.54% | 64.74% | 68.58% | 73.7% | 78.87% | 80.9% | 73.05% | 81.14% | 84.43% | - |
| Selling, General & Admin | 20.79M | 18.65M | 19.41M | 22.28M | 16.94M | 22.82M | 25.39M | 23.46M | 23.59M | 23.8M |
| SG&A % of Revenue | 65.46% | 59.3% | 65.01% | 70.53% | 73.35% | 76.12% | 70.21% | 70.34% | 70.29% | - |
| Research & Development | 1.93M | 1.71M | 1.06M | 1M | 1.27M | 1.43M | 1.03M | 1.32M | 883K | 554K |
| R&D % of Revenue | 6.07% | 5.44% | 3.57% | 3.17% | 5.52% | 4.78% | 2.85% | 3.95% | 2.63% | - |
| Other Operating Expenses | 21K | 17K | 200K | 0 | 0 | 0 | 0 | 2.28M | 3.86M | 1000K |
| Operating Income | -3.6M▲ 0% | -2.41M▲ 33.0% | -3.35M▼ 39.2% | -3.01M▲ 10.3% | -4.08M▼ 35.4% | -4.4M▼ 8.0% | -4.65M▼ 5.6% | -8.6M▼ 85.1% | -9.26M▼ 7.6% | -10.32M▲ 0% |
| Operating Margin % | -11.33% | -7.66% | -11.24% | -9.53% | -17.65% | -14.68% | -12.86% | -25.79% | -27.58% | -33.32% |
| Operating Income Growth % | 78.17% | 33% | -39.21% | 10.28% | -35.42% | -8% | -5.61% | -85.07% | -7.57% | - |
| EBITDA | 2.77M | 3.93M | 2.04M | 1.81M | -165K | -316K | 1.04M | -2.7M | -3.95M | -5.45M |
| EBITDA Margin % | 8.72% | 12.48% | 6.84% | 5.73% | -0.71% | -1.05% | 2.87% | -8.1% | -11.76% | -17.59% |
| EBITDA Growth % | 122.29% | 41.78% | -47.99% | -11.31% | -109.11% | -91.52% | 428.8% | -360.06% | -46.11% | -70.41% |
| D&A (Non-Cash Add-back) | 6.37M | 6.34M | 5.4M | 4.82M | 3.91M | 4.09M | 5.69M | 5.9M | 5.31M | 4.88M |
| EBIT | -3.6M | -1.8M | -3.35M | -3.01M | -3.93M | -2.36M | -4.56M | -9.28M | -8.15M | -9.22M |
| Net Interest Income | -4.9M | -3.2M | -1.14M | -515K | -61K | -299K | -837K | -1.41M | -1.86M | -1.57M |
| Interest Income | 0 | 0 | 0 | 0 | 150K | 15K | 89K | 231K | 242K | 419K |
| Interest Expense | 4.9M | 3.2M | 1.14M | 515K | 211K | 314K | 926K | 1.64M | 2.11M | 1.99M |
| Other Income/Expense | 517K | -19.59M | -942K | -929K | -61K | 1.73M | -837K | -2.32M | -1M | -887K |
| Pretax Income | -3.08M▲ 0% | -18.7M▼ 507.2% | -4.3M▲ 77.0% | -3.94M▲ 8.3% | -4.14M▼ 5.0% | -2.67M▲ 35.4% | -5.49M▼ 105.3% | -10.92M▼ 99.1% | -10.26M▲ 6.1% | -11.21M▲ 0% |
| Pretax Margin % | -9.7% | -59.47% | -14.39% | -12.47% | -17.92% | -8.91% | -15.17% | -32.74% | -30.56% | -36.18% |
| Income Tax | 255K | 129K | -264K | -149K | 275K | 34K | 63K | -92K | -170K | -170K |
| Effective Tax Rate % | -8.28% | -0.69% | 6.14% | 3.78% | -6.65% | -1.27% | -1.15% | 0.84% | 1.66% | 1.52% |
| Net Income | -3.33M▲ 0% | -21.51M▼ 545.1% | -4.03M▲ 81.3% | -3.79M▲ 6.0% | -4.41M▼ 16.4% | -2.71M▲ 38.7% | -5.55M▼ 105.1% | -10.83M▼ 95.2% | -10.09M▲ 6.9% | -11.04M▲ 0% |
| Net Margin % | -10.5% | -68.41% | -13.51% | -12% | -19.11% | -9.03% | -15.35% | -32.47% | -30.05% | -35.64% |
| Net Income Growth % | 88.05% | -545.1% | 81.25% | 6.03% | -16.41% | 38.67% | -105.06% | -95.17% | 6.87% | -17.66% |
| Net Income (Continuing) | -3.33M | -21.51M | -4.03M | -3.79M | -4.41M | -2.71M | -5.55M | -10.83M | -10.09M | -11.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.44▲ 0% | -3.26▼ 126.4% | -0.15▲ 95.4% | -0.12▲ 20.0% | -0.13▼ 8.3% | -0.08▲ 38.8% | -0.16▼ 101.3% | -0.31▼ 93.8% | -0.26▲ 16.1% | -0.25▲ 0% |
| EPS Growth % | 99.12% | -126.39% | 95.4% | 20% | -8.33% | 38.85% | -101.26% | -93.75% | 16.13% | -335.46% |
| EPS (Basic) | -3.77 | -3.26 | -0.15 | -0.12 | -0.13 | -0.08 | -0.16 | -0.31 | -0.26 | - |
| Diluted Shares Outstanding | 2.32M | 6.6M | 27.17M | 31.98M | 33.61M | 34.05M | 34.71M | 34.92M | 38.07M | 44.81M |
| Basic Shares Outstanding | 884.61K | 6.6M | 27.17M | 31.98M | 33.61M | 34.05M | 34.71M | 34.92M | 38.07M | 44.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SSKN Balance Sheet
STRATA Skin Sciences, Inc. (SSKN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.75M | 10.75M | 23.21M | 23.55M | 24.83M | 19.97M | 17.5M | 15.54M | 16.59M | 14.27M |
| Cash & Short-Term Investments | 3.93M | 4.07M | 16.49M | 8.13M | 10.6M | 12.59M | 5.43M | 6.78M | 7.26M | 7.08M |
| Cash Only | 3.93M | 4.07M | 16.49M | 8.13M | 10.6M | 12.59M | 5.43M | 6.78M | 7.26M | 7.08M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.39M | 3.14M | 3.39M | 4.39M | 2.94M | 3.43M | 4.47M | 4.44M | 5.25M | 3.5M |
| Days Sales Outstanding | 38.96 | 36.45 | 41.48 | 50.68 | 46.54 | 41.8 | 45.13 | 48.58 | 57.13 | 52.39 |
| Inventory | 2.82M | 3.01M | 2.79M | 3.03M | 3.44M | 3.49M | 5.55M | 2.67M | 2.25M | 3.06M |
| Days Inventory Outstanding | 81.37 | 81.37 | 80.08 | 97.64 | 140.36 | 125.75 | 140.67 | 65.49 | 56.61 | 78.09 |
| Other Current Assets | 617K | 533K | 0 | 7.5M | 7.51M | 0 | 2.05M | 1.65M | 1.83M | 634K |
| Total Non-Current Assets | 32.44M | 27.88M | 24.3M | 23.79M | 21.95M | 26.62M | 34.77M | 26.47M | 19.56M | 16.45M |
| Property, Plant & Equipment | 10.18M | 7.7M | 5.3M | 6.68M | 6.52M | 7.52M | 8.47M | 12.4M | 11.32M | 10.56M |
| Fixed Asset Turnover | 3.12x | 4.08x | 5.63x | 4.73x | 3.54x | 3.99x | 4.27x | 2.69x | 2.96x | 2.93x |
| Goodwill | 8.8M | 8.8M | 8.8M | 8.8M | 8.8M | 8.8M | 8.8M | 6.52M | 2.66M | 1.43M |
| Intangible Assets | 13.41M | 11.32M | 9.77M | 7.96M | 6.34M | 10.08M | 17.39M | 7.32M | 5.35M | 4.22M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 46K | 48K | 428K | 347K | 282K | 216K | 98K | 231K | 231K | 924K |
| Total Assets | 43.19M▲ 0% | 38.63M▼ 10.6% | 47.51M▲ 23.0% | 47.34M▼ 0.3% | 46.78M▼ 1.2% | 46.59M▼ 0.4% | 52.27M▲ 12.2% | 42.02M▼ 19.6% | 36.16M▼ 13.9% | 30.72M▲ 0% |
| Asset Turnover | 0.74x | 0.81x | 0.63x | 0.67x | 0.49x | 0.64x | 0.69x | 0.79x | 0.93x | 0.94x |
| Asset Growth % | -15.92% | -10.56% | 22.98% | -0.35% | -1.19% | -0.4% | 12.19% | -19.62% | -13.94% | -74.37% |
| Total Current Liabilities | 6.13M | 7.67M | 8.62M | 17.43M | 18.84M | 12.8M | 13.43M | 12.17M | 14.63M | 15.03M |
| Accounts Payable | 1.85M | 2.28M | 1.76M | 1.88M | 2.76M | 2.82M | 3.42M | 3.34M | 2.43M | 2.96M |
| Days Payables Outstanding | 53.53 | 61.57 | 50.56 | 60.64 | 112.65 | 101.71 | 86.86 | 81.91 | 61.32 | 77.74 |
| Short-Term Debt | 2.05M | 2.74M | 252K | 7.28M | 8.75M | 0 | 0 | 0 | 0 | 2.14M |
| Deferred Revenue (Current) | 235K | 291K | 2.1M | 2.83M | 2.26M | 3.29M | 2.78M | 2.12M | 2.24M | 9.37M |
| Other Current Liabilities | 376K | 2.06M | 506K | 748K | 891K | 2.05M | 4.87M | 1.73M | 2.81M | 5.42M |
| Current Ratio | 1.75x | 1.40x | 2.69x | 1.35x | 1.32x | 1.56x | 1.30x | 1.28x | 1.13x | 1.13x |
| Quick Ratio | 1.29x | 1.01x | 2.37x | 1.18x | 1.14x | 1.29x | 0.89x | 1.06x | 0.98x | 0.98x |
| Cash Conversion Cycle | 66.81 | 56.25 | 71 | 87.68 | 74.25 | 65.84 | 98.94 | 32.17 | 52.41 | 52.74 |
| Total Non-Current Liabilities | 22.34M | 8.71M | 7.64M | 1.26M | 2.05M | 8.38M | 17.02M | 17.15M | 16.56M | 14.37M |
| Long-Term Debt | 21.78M | 7.85M | 7.14M | 0 | 1.05M | 7.32M | 7.48M | 15.04M | 15.19M | 13.44M |
| Capital Lease Obligations | 0 | 0 | 0 | 1.08M | 710K | 392K | 610K | 237K | 919K | 3.27M |
| Deferred Tax Liabilities | 359K | 414K | 111K | -115K | 254K | 266K | 306K | 186K | 0 | 0 |
| Other Non-Current Liabilities | 202K | 511K | 388K | 178K | 34K | 0 | 8.31M | 1.69M | 449K | 1.3M |
| Total Liabilities | 28.47M | 16.39M | 16.26M | 18.69M | 20.89M | 21.18M | 30.44M | 29.33M | 31.18M | 29.4M |
| Total Debt | 23.83M | 10.6M | 7.4M | 8.67M | 10.88M | 8.03M | 8.44M | 15.63M | 16.44M | 16.31M |
| Net Debt | 19.91M | 6.53M | -9.09M | 537K | 278K | -4.56M | 3.01M | 8.85M | 9.18M | 9.24M |
| Debt / Equity | 1.62x | 0.48x | 0.24x | 0.30x | 0.42x | 0.32x | 0.39x | 1.23x | 3.31x | 3.31x |
| Debt / EBITDA | 8.61x | 2.70x | 3.62x | 4.79x | - | - | 8.12x | - | - | -2.99x |
| Net Debt / EBITDA | 7.19x | 1.66x | -4.45x | 0.30x | - | - | 2.89x | - | - | -1.70x |
| Interest Coverage | -0.73x | -0.75x | -2.94x | -5.84x | -19.32x | -14.02x | -5.02x | -5.25x | -4.39x | -4.63x |
| Total Equity | 14.72M▲ 0% | 22.25M▲ 51.1% | 31.25M▲ 40.5% | 28.65M▼ 8.3% | 25.89M▼ 9.6% | 25.41M▼ 1.8% | 21.83M▼ 14.1% | 12.69M▼ 41.9% | 4.97M▼ 60.8% | 1.31M▲ 0% |
| Equity Growth % | -8.5% | 51.13% | 40.47% | -8.3% | -9.64% | -1.85% | -14.1% | -41.88% | -60.81% | -315.21% |
| Book Value per Share | 6.36 | 3.37 | 1.15 | 0.90 | 0.77 | 0.75 | 0.63 | 0.36 | 0.13 | 0.03 |
| Total Shareholders' Equity | 14.72M | 22.25M | 31.25M | 28.65M | 25.89M | 25.41M | 21.83M | 12.69M | 4.97M | 1.31M |
| Common Stock | 11K | 4K | 30K | 33K | 34K | 34K | 35K | 4K | 4K | 5K |
| Retained Earnings | -210.57M | -229.41M | -210.77M | -214.56M | -218.97M | -221.68M | -227.23M | -238.06M | -248.14M | -254.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2K | -10.73M | -13.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SSKN Cash Flow Statement
STRATA Skin Sciences, Inc. (SSKN) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 322K | 4.14M | 2.9M | 2.23M | 2.1M | 1.51M | -1.11M | -519K | 188K | 188K |
| Operating CF Margin % | 1.01% | 13.16% | 9.7% | 7.06% | 9.08% | 5.03% | -3.06% | -1.56% | 0.56% | - |
| Operating CF Growth % | 104.89% | 1185.71% | -30.05% | -23.03% | -5.97% | -28.05% | -173.47% | 53.16% | 136.22% | -371.35% |
| Net Income | -3.33M | -18.83M | -4.03M | -3.79M | -4.41M | -2.71M | -5.55M | -10.83M | -10.09M | -11.04M |
| Depreciation & Amortization | 6.37M | 6.34M | 5.4M | 4.82M | 3.91M | 4.09M | 5.69M | 5.9M | 5.31M | 4.88M |
| Stock-Based Compensation | 113K | 186K | 904K | 1.2M | 1.63M | 1.64M | 1.47M | 1.3M | 427K | 383K |
| Deferred Taxes | 240K | 55K | -303K | -111K | 254K | 12K | 40K | -120K | -186K | 0 |
| Other Non-Cash Items | -2.48M | 15.03M | 717K | 247K | 114K | -1.85M | 316K | 3.29M | 4.04M | 3.67M |
| Working Capital Changes | -583K | 1.36M | 214K | -133K | 596K | 324K | -3.07M | -69K | 688K | 257K |
| Change in Receivables | 558K | 184K | -222K | -1.04M | 1.35M | -490K | -1.15M | 141K | -631K | 965K |
| Change in Inventory | 1.31M | -193K | 215K | -233K | -417K | -45K | -1.52M | 689K | 572K | -72K |
| Change in Payables | -2.6M | 381K | -513K | 116K | 884K | 58K | 603K | -100K | -954K | 1.16M |
| Cash from Investing | -868K | -2.19M | -1.78M | -2.79M | -2.16M | -7.13M | -4.18M | -5.02M | -1.64M | -1.66M |
| Capital Expenditures | -1.01M | -1.74M | -1.76M | -2.79M | -2.16M | -3.65M | -3.55M | -5.02M | -1.64M | -1.66M |
| CapEx % of Revenue | 3.17% | 5.53% | 5.9% | 8.84% | 9.35% | 12.19% | 9.82% | 15.05% | 4.87% | - |
| Acquisitions | 125K | 0 | 0 | 0 | 0 | -3.47M | -631K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 15K | -455K | -23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.17M | -1.8M | 11.31M | -296K | 2.55M | 92K | -500K | 6.86M | 1.93M | 2.19M |
| Debt Issued (Net) | 1.17M | -1.8M | -3.36M | -296K | 2.53M | 225K | 0 | 7M | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 0 | 18K | 0 | 0 | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -2.34M | 0 | 0 | -133K | -500K | -139K | -18K | 0 |
| Net Change in Cash | 625K▲ 0% | 141K▼ 77.4% | 12.42M▲ 8707.1% | -858K▼ 106.9% | 2.48M▲ 389.4% | -5.53M▼ 322.6% | -5.79M▼ 4.8% | 1.32M▲ 122.8% | 477K▼ 63.9% | -1.32M▲ 0% |
| Free Cash Flow | -686K▲ 0% | 2.4M▲ 450.0% | 1.13M▼ 52.8% | -562K▼ 149.6% | -63K▲ 88.8% | -2.15M▼ 3304.8% | -4.66M▼ 117.2% | -5.54M▼ 18.8% | -1.45M▲ 73.9% | -3.51M▲ 0% |
| FCF Margin % | -2.16% | 7.63% | 3.8% | -1.78% | -0.27% | -7.16% | -12.89% | -16.6% | -4.31% | -11.34% |
| FCF Growth % | 91.71% | 450% | -52.77% | -149.56% | 88.79% | -3304.76% | -117.25% | -18.84% | 73.85% | -76.13% |
| FCF per Share | -0.30 | 0.36 | 0.04 | -0.02 | -0.00 | -0.06 | -0.13 | -0.16 | -0.04 | -0.04 |
| FCF Conversion (FCF/Net Income) | -0.10x | -0.19x | -0.72x | -0.59x | -0.48x | -0.56x | 0.20x | 0.05x | -0.02x | 0.32x |
| Interest Paid | 0 | 2.21M | 1.01M | 766K | 0 | 0 | 744K | 1.42M | 1.97M | 940K |
| Taxes Paid | 0 | 28K | 17K | 0 | 0 | 0 | 19K | 22K | 23K | 0 |
SSKN Key Ratios
STRATA Skin Sciences, Inc. (SSKN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -21.65% | -116.41% | -15.08% | -12.65% | -16.18% | -10.55% | -23.49% | -62.75% | -114.22% | -840.18% |
| Return on Invested Capital (ROIC) | -7.85% | -5.7% | -9.88% | -8.79% | -11.04% | -14.04% | -15.26% | -27.83% | -38.9% | -38.9% |
| Gross Margin | 60.21% | 57.08% | 57.34% | 64.17% | 61.21% | 66.22% | 60.2% | 55.34% | 56.85% | 57.76% |
| Net Margin | -10.5% | -68.41% | -13.51% | -12% | -19.11% | -9.03% | -15.35% | -32.47% | -30.05% | -35.64% |
| Debt / Equity | 1.62x | 0.48x | 0.24x | 0.30x | 0.42x | 0.32x | 0.39x | 1.23x | 3.31x | 3.31x |
| Interest Coverage | -0.73x | -0.75x | -2.94x | -5.84x | -19.32x | -14.02x | -5.02x | -5.25x | -4.39x | -4.63x |
| FCF Conversion | -0.10x | -0.19x | -0.72x | -0.59x | -0.48x | -0.56x | 0.20x | 0.05x | -0.02x | 0.32x |
| Revenue Growth | 71.71% | -0.97% | -5.07% | 5.8% | -26.9% | 29.83% | 20.63% | -7.75% | 0.61% | -5.19% |
SSKN Frequently Asked Questions
STRATA Skin Sciences, Inc. (SSKN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
STRATA Skin Sciences, Inc. (SSKN) reported $31.0M in revenue for fiscal year 2024.
STRATA Skin Sciences, Inc. (SSKN) grew revenue by 0.6% over the past year. Growth has been modest.
STRATA Skin Sciences, Inc. (SSKN) reported a net loss of $11.0M for fiscal year 2024.
Dividend & Returns
STRATA Skin Sciences, Inc. (SSKN) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.
STRATA Skin Sciences, Inc. (SSKN) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More SSKN
STRATA Skin Sciences, Inc. (SSKN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates